IDEAYA Biosciences Completes Targeted Full Enrollment in Randomized Pivotal Phase 2/3 Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in First-line HLA*A2-Negative Metastatic Uveal Melanoma
MWN-AI** Summary
IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a notable player in precision oncology, has successfully completed the targeted full enrollment of 435 patients in its pivotal Phase 2/3 trial, dubbed OptimUM-02. This study evaluates the efficacy of darovasertib, an investigational oral protein kinase C (PKC) inhibitor, in combination with Pfizer’s crizotinib, an oral c-MET inhibitor, specifically for patients with first-line HLA*A2-negative metastatic uveal melanoma (mUM). This form of cancer is aggressive with limited treatment options, underscoring the importance of this trial.
The primary objectives of OptimUM-02 include assessing median progression-free survival (PFS) and overall survival (OS). IDEAYA anticipates that topline data, particularly concerning median PFS, will be available in the first quarter of 2026. If the results are supportive, the company plans to file for accelerated approval with the U.S. FDA. Median OS data will be crucial for a potential full approval filing later on.
IDEAYA's earlier findings from the Phase 1/2 trial, OptimUM-01, indicated promising outcomes, with a median OS of 21.1 months and a median PFS of 7.0 months. Such results enhance the clinical potential of darovasertib to offer substantial benefits to patients facing this challenging diagnosis.
IDEAYA's proactive approach not only reflects its commitment to addressing unmet medical needs but also showcases its robust pipeline, including ongoing enrollment in a pivotal Phase 3 trial of single-agent darovasertib in early-stage primary uveal melanoma (OptimUM-10). The company holds FDA Breakthrough Therapy and Orphan Drug Designations for darovasertib, which may expedite its development and market entry.
MWN-AI** Analysis
IDEAYA Biosciences (NASDAQ: IDYA) recently announced the completion of targeted enrollment in its pivotal Phase 2/3 trial (OptimUM-02) for darovasertib in combination with crizotinib for HLA*A2-negative metastatic uveal melanoma. This is a significant milestone as it paves the way for potential regulatory approvals. The trial includes 435 patients and aims to assess the drug's efficacy and safety profile, with median progression-free survival (PFS) and overall survival (OS) data expected by Q1 2026.
Investors should note the implications of this trial's outcomes on the company’s stock performance. The rare and aggressive nature of metastatic uveal melanoma, combined with limited treatment options, underscores the potential market for darovasertib and crizotinib. Given IDEAYA's prior success in the OptimUM-01 trial, which indicated promising survival rates, analysts suggest that positive data from OptimUM-02 could lead to accelerated regulatory filings and possible commercialization in the near future.
The drug has already received FDA Breakthrough Therapy and Fast Track designations, which may expedite its approval process. These designations enhance investor sentiment but also come with heightened scrutiny and risks related to clinical outcomes. Therefore, while the stock may see volatility based on trial updates, the prospects of successful trial results could provide substantial upside.
It's important for potential investors to monitor upcoming trial data closely, as favorable results may result in a price surge, while negative outcomes could lead to significant declines. Given the current state of the company's pipeline and market position, a cautious but optimistic approach might be warranted, particularly for those with a higher risk tolerance looking to capitalize on innovations within oncology.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
PR Newswire
- Targeted enrollment of 435 patients to enable potential full approval filing has been completed in OptimUM-02 trial
- Topline data, including median PFS, are expected in 1Q 2026 to support a potential accelerated approval filing in the United States
SOUTH SAN FRANCISCO, Calif., Dec. 11, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a leading precision medicine oncology company, today announced it has completed its targeted full enrollment of 435 patients in the registration-enabling Phase 2/3 trial (OptimUM-02) evaluating darovasertib, the company's investigational oral protein kinase C (PKC) inhibitor, in combination with Pfizer's crizotinib, an oral c-MET inhibitor, in first line (1L) HLA*A2-negative metastatic uveal melanoma (mUM). IDEAYA expects to report median progression-free survival (PFS) data from this trial in the first quarter 2026 to support a potential accelerated approval filing in the United States. Median overall survival (mOS) data from OptimUM-02, once available, will be used to support a potential full approval filing. Metastatic uveal melanoma is a rare, aggressive form of ocular cancer with limited treatment options and historically poor survival outcomes.
"We are very pleased to announce that we have achieved the target enrollment to enable potential full approval filing in our Phase 2/3 registration-enabling trial of darovasertib in combination with crizotinib in first-line HLA*A2-negative metastatic uveal melanoma. This milestone reflects both the clear unmet need in metastatic uveal melanoma, as well as the strong clinical interest in our darovasertib program. Moreover, the promising overall survival data and broader clinical efficacy demonstrated in the recently reported median overall survival results from the Phase 1/2 clinical trial (OptimUM-01) of this combination in metastatic uveal melanoma are indicative of the clinical potential of darovasertib to meaningfully impact patients with this devastating disease. With target full enrollment now complete, we look forward to the availability of median PFS data we project from OptimUM-02 in the first quarter of next year, and, if approved, making darovasertib in combination with crizotinib available to patients with HLA*A2-negative metastatic uveal melanoma as a first-line treatment as expeditiously as possible," said Yujiro S. Hata, President and Chief Executive Officer, IDEAYA Biosciences.
OptimUM-02 is a multi-arm, multi-stage, open-label Phase 2/3 trial with patients randomized to receive either the darovasertib and crizotinib combination or investigator's choice of treatment (pembrolizumab, ipilimumab + nivolumab, or dacarbazine). The primary endpoints are median PFS and median OS, which will be used to support a potential accelerated approval and full approval in the United States, respectively. In October 2025, IDEAYA presented data from its single-arm, Phase 2 trial (OptimUM-01) of the darovasertib and crizotinib combination at the Society for Melanoma Research (SMR) Congress that demonstrated a 21.1 month median OS and 7.0 months median PFS in 1L mUM, including both HLA*A2-negative and HLA*A2-positive patients.
Darovasertib has received U.S. Food and Drug Administration (FDA) Breakthrough Therapy Designation as neoadjuvant therapy in enucleation recommended primary uveal melanoma (UM) and Fast Track designation for darovasertib in combination with crizotinib in adult patients with metastatic UM. Darovasertib has also been designated as an Orphan Drug by the U.S. FDA in UM, including in metastatic UM. IDEAYA is currently enrolling patients in a pivotal Phase 3 trial of single-agent darovasertib in the neoadjuvant setting of primary UM (OptimUM-10).
About IDEAYA Biosciences
IDEAYA is a precision medicine oncology company committed to the discovery, development, and commercialization of transformative therapies for cancer. Our approach integrates expertise in small-molecule drug discovery, structural biology and bioinformatics with robust internal capabilities in identifying and validating translational biomarkers to develop tailored, potentially first-in-class targeted therapies aligned to the genetic drivers of disease. We have built a deep pipeline of product candidates focused on synthetic lethality and antibody-drug conjugates, or ADCs, for molecularly defined solid tumor indications. Our mission is to bring forth the next wave of precision oncology therapies that are more selective, more effective, and deeply personalized with the goal of altering the course of disease and improving clinical outcomes for patients with cancer.
Forward-Looking Statements
This press release contains forward-looking statements, including, but not limited to, statements related to (i) the timing and content of clinical trial programs and updates, including enrollment achievements, regulatory updates, clinical trial data readouts; (ii) the potential for an accelerated and full approval for darovasertib; (iii) the potential therapeutic benefit of darovasertib, including in combination with crizotinib; and (iv) the timing of development and regulatory milestones. Clinical trial results, preliminary or otherwise, are not necessarily predictive of future clinical trial results and/or approval. Neither Breakthrough Therapy nor Orphan Drug Designation necessarily translates into approval of the drug. Such forward-looking statements involve substantial risks and uncertainties that could cause IDEAYA's preclinical and clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the drug development process, including IDEAYA's programs' early stage of development, the process of designing and conducting preclinical and clinical trials, the regulatory approval processes, the timing of regulatory filings, the challenges associated with manufacturing and commercializing drug products, IDEAYA's ability to successfully establish, protect and defend its intellectual property, and other matters that could affect the sufficiency of existing cash to fund operations. IDEAYA undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of IDEAYA in general, see IDEAYA's Annual Report on Form 10-K dated February 18, 2025 and any current and periodic reports filed with the U.S. Securities and Exchange Commission.
Investor and Media Contact
IDEAYA Biosciences
Joshua Bleharski, Ph.D.
Chief Financial Officer
investor@ideayabio.com
SOURCE IDEAYA Biosciences, Inc.
FAQ**
What are the anticipated implications for IDEAYA Biosciences Inc. (IDYA) if the median progression-free survival (PFS) data from the OptimUM-02 trial supports an accelerated approval for darovasertib in combination with crizotinib?
How might the recent median overall survival data reported from the OptimUM-01 trial influence investor sentiment towards IDEAYA Biosciences Inc. (IDYA) and its ongoing clinical trials?
Given that darovasertib has received Breakthrough Therapy Designation from the FDA, what strategies is IDEAYA Biosciences Inc. (IDYA) implementing to expedite the drug's development and potential market entry for metastatic uveal melanoma?
How does IDEAYA Biosciences Inc. (IDYA) plan to address the potential risks and uncertainties associated with the ongoing clinical trials for darovasertib, particularly in terms of funding operations and maintaining investor confidence?
**MWN-AI FAQ is based on asking OpenAI questions about IDEAYA Biosciences Inc. (NASDAQ: IDYA).
NASDAQ: IDYA
IDYA Trading
-3.12% G/L:
$33.87 Last:
187,349 Volume:
$34.39 Open:
